Target
CYP11A1
2 products, 2 indications
Indications
Advanced solid tumors (ovarian, prostate, breast cancer) (1 products)
Metastatic Castration-Resistant Prostate Cancer (1 products)
Loading...
1 drug
3 abstracts
Abstract
ODM-209, a CYP 11A1 inhibitor in patients with mCRPC: Results from the STESIDES phase 1 study.Org: Rigshospitalet University Hospital of Copenhagen, HUCH, Finland, Tampere University Hospital (TAYS), Espoo,
Abstract
CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy: Phase 3 MK-5684-003 trial.Org: Fred Hutchinson Cancer Center, University of Washington and Fred Hutchinson Cancer Research Centre, Merck & Co., Inc., Rahway, NJ, University of Minnesota Masonic Cancer Center, Minneapolis, MN,
Abstract
Examining clinical trial eligibility for oncology patients with human immunodeficiency virus (HIV): A global cross-sectional analysis.Org: The Christie NHS Foundation Trust, University of Manchester and The Christie NHS Foundation Trust, The Christie NHS Foundation Trust and The University of Manchester,
Drug
OVV-01